Tristel PLC Regulatory approval in Australia for surface range (4912J)
September 12 2016 - 2:00AM
UK Regulatory
TIDMTSTL
RNS Number : 4912J
Tristel PLC
12 September 2016
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014
Tristel plc
("Tristel" or the "Company")
Regulatory approval in Australia for surface disinfectant
products
Tristel plc (AIM: TSTL), the manufacturer of infection control,
contamination control and hygiene products, announces that it has
received regulatory approval for its Fuse for Surfaces and Jet for
Surfaces disinfectant products from the Therapeutic Goods
Association (TGA), the body that regulates disinfectant use in
Australia. Both Tristel products have been approved as Hospital
Grade Disinfectants and will be permitted to make efficacy claims
against bacterial spores including Clostridium difficile.
The Australian hospital market constitutes 750 public hospitals
and 290 private hospitals, and the problems associated with
hospital-acquired infections in Australia are very similar to the
United Kingdom. In the UK, Fuse and Jet for Surfaces generated
sales of approximately GBP1.2 million in the 2016 financial
year.
Tristel has had a presence in the Australian hospital market
since 2011 when it received its first approval from the TGA for its
Wipes System for the disinfection of small medical instruments.
From 2011 to July 2016 Tristel sold its Wipes System via a
distributor. During the year ended 30 June 2016 the distributor's
sales of the Wipes System were approximately AU$3 million (c.
GBP1.7 million). On 18 July Tristel purchased the distributor's
business and established a direct presence in the Australian
healthcare market via its wholly-owned subsidiary, Tristel Pty
Limited.
Paul Swinney, CEO, commented: "Just as the Wipes System approval
took nearly two years to obtain from the TGA, so has the approval
for our two surface disinfection products. The wait will certainly
be worthwhile as the advantages that our products enjoy in the
United Kingdom are the same as they will enjoy in Australia.
Hospitals in Australia are experiencing infection outbreak problems
as hospitals here have and, as we have repeatedly demonstrated, our
surface disinfection products are widely recognised as the best
defence against Clostridium difficile."
Click here for RNS Reach: "Success in controlling Clostridium
difficile outbreaks" (24 April 2014) or view via this link:
http://bit.ly/2c806WE
For further information please contact:
Tristel plc Tel: 01638 721 500
Paul Swinney, Chief
Executive Officer
Liz Dixon, Finance
Director
Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
finnCap Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate
Finance)
Alice Lane (Corporate
Broking)
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAURVRRNVAKAAR
(END) Dow Jones Newswires
September 12, 2016 02:00 ET (06:00 GMT)
Tristel (LSE:TSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tristel (LSE:TSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024